Updating results

Non-steroidal anti-inflammatory drugs (KTT13)

KTT13 Non-steroidal anti-inflammatory drugs Options for local implementation Review

Key therapeutic topic Published January 2015 Last updated February 2018

Biosimilar medicines (KTT15)

KTT15 Biosimilar medicines Options for local implementation Biosimilar medicines have

Key therapeutic topic Published February 2016 Last updated February 2018

Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

Advice on the use of Reveal LINQ insertable cardiac monitor (ICM) to detect atrial fibrillation (AF) after cryptogenic stroke to aid local decision-making

Medtech innovation briefing Published February 2018

Coban 2 for venous leg ulcers (MIB140)

Advice on the use of Coban 2 for venous leg ulcers to aid local decision-making

Medtech innovation briefing Published February 2018

EpiFix for chronic wounds (MIB139)

Advice on the use of EpiFix (an allograft comprising dehydrated human amnion/chorion membrane tissue/dHACM) for chronic wounds to aid local decision-making

Medtech innovation briefing Published January 2018

Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)

Advice on the use of minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones to aid local decision-making

Medtech innovation briefing Published January 2018

MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

Advice on the use of the MammaTyper in vitro diagnostic test for determining breast cancer subtypes to aid local decision-making

Medtech innovation briefing Published January 2018

Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

Advice on the use of plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) to aid local decision-making

Medtech innovation briefing Published January 2018

Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

This advice has been replaced by NICE diagnostics guidance 37.

Medtech innovation briefing Published January 2018

TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)

Advice on the use of the TYM smartphone otoscope (using Apple iOS device) for imaging/videoing the external ear canal and eardrum to aid local decision-making

Medtech innovation briefing Published January 2018

Next-generation sequencing panel for solid tumour cancers in children (MIB133)

Advice on the use of the next-generation sequencing (NGS) panel for solid tumour cancers in children to aid local decision-making

Medtech innovation briefing Published January 2018

In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated with anticoagulation drug therapy. [Patients with a previous score of 2 or above using CHADS2, recorded prior to [implementation date] should be included in the denominator.]

In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated...

General practice indicator suitable for use in the QOF Published December 2017

The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)

The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring...

General practice indicator suitable for use in the QOF Published December 2017

Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

Advice on the use of point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease

Medtech innovation briefing Published December 2017

The proportion of eligible people aged 60-74 years whose record shows a bowel screening test has been performed within the last 2.5 years

The proportion of eligible people aged 60-74 years whose record shows a bowel screening test has been performed within the last 2.5 years

Clinical Commissioning Group indicator Published November 2017

The proportion of women aged 50-70 years whose record shows a breast screening test has been performed within the last 3 years

The proportion of women aged 50-70 years whose record shows a breast screening test has been performed within the last 3 years Subject(s):

Clinical Commissioning Group indicator Published November 2017

Proportion of patients with atrial fibrillation on anticoagulation admitted to hospital for stroke

Proportion of patients with atrial fibrillation on anticoagulation admitted to hospital for stroke Subject(s): Atrial fibrillation

Clinical Commissioning Group indicator Published November 2017

Health app: GDm-Health for people with gestational diabetes (MIB131)

Advice on the GDm-Health app to remotely monitor blood glucose in people with gestational diabetes (diabetes in pregnancy) to aid local decision-making

Medtech innovation briefing Published November 2017

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Health app: ChatHealth communication platform in school nursing services (MIB130)

Advice on the use of the ChatHealth app for anonymous and confidential communication between patients and healthcare professionals in school nursing services

Medtech innovation briefing Published November 2017

Health app: Sleepio for adults with poor sleep (MIB129)

Advice on the use of the Sleepio health app to help adults with poor sleep improve sleep through cognitive behavioural therapy, to aid local decision-making

Medtech innovation briefing Published November 2017

The proportion of women eligible for screening and aged 25 – 49 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 3.5 years

The proportion of women eligible for screening and aged 25 – 49 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 3.5 years

General practice indicator suitable for use in the QOF Published November 2017

HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)

Advice on the use of HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (NSCLC) to aid local decision-making

Medtech innovation briefing Published November 2017

Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)

Advice on the use of radiation dose monitoring software for medical imaging with ionising radiation to aid local decision-making

Medtech innovation briefing Published October 2017

Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)

This advice has been replaced by NICE diagnostics guidance 36.

Medtech innovation briefing Published October 2017

PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)

Advice on the use of PleuraFlow Active Clearance Technology (ACT) for maintaining chest tube patency to aid local decision-making

Medtech innovation briefing Published October 2017

Mepilex Border dressings for preventing pressure ulcers (MIB124)

This advice has been updated and replaced by NICE medical technologies guidance 40.

Medtech innovation briefing Published October 2017

The percentage of patients with diabetes who have a record of an albumin:creatinine ratio (ACR) test in the preceding 15 months

NICE indicators. NM59 diabetes guidance.

General practice indicator suitable for use in the QOF Published October 2017

The practice can produce a register of all patients aged 16 years and over with rheumatoid arthritis

NICE indicators. NM55 rheumatoid arthritis guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with rheumatoid arthritis aged 30-84 years who have had a cardiovascular risk assessment using a CVD risk assessment tool adjusted for RA in the preceding 15 months

NICE indicators. NM56 rheumatoid arthritis guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with rheumatoid arthritis, on the register, who have had a face-to-face review in the preceding 12 months

NICE indicators. NM58 rheumatoid arthritis guidance.

General practice indicator suitable for use in the QOF Published October 2017

The contractor establishes and maintains a register of patients aged 18 years or over with CKD with classification of categories G3a to G5 (previously stage 3 to 5)

NICE indicators. NM83 chronic kidney disease guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients on the CKD register who have hypertension and proteinuria and who are currently being treated with renin-angiotensin system antagonists

NICE indicators. NM84 chronic kidney disease guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients aged 40 years and over with a blood pressure measurement recorded in the preceding 5 years

NICE indicators. NM61 blood pressure guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients aged 50-90 years with rheumatoid arthritis who have had an assessment of fracture risk using a risk assessment tool adjusted for RA in the preceding 27 months

NICE indicators. NM57 rheumatoid arthritis guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have been reviewed within 10-35 days of the date of diagnosis

NICE indicators. NM50 depression guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have had a bio-psychosocial assessment by the point of diagnosis

NICE indicators. NM49 depression guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of male patients with diabetes with a record of being asked about erectile dysfunction in the preceding 15 months

NICE indicators. NM51 diabetes guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with peripheral arterial disease in whom the last measured total cholesterol (measured in preceding 15 months) is 5.0mmol/l or less

NICE indicators. NM35 peripheral arterial disease guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with hypertension aged 16 to 74 years in whom there is an annual assessment of physical activity, using GPPAQ, in the preceding 15 months

NICE indicators. NM36 physical activity guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with diabetes who have a record of a dietary review by a suitably competent professional in the preceding 15 months

NICE indicators. NM28 diabetes guidance.

General practice indicator suitable for use in the QOF Published October 2017

The percentage of patients with peripheral arterial disease with a record in the preceding 15 months that aspirin or an alternative anti-platelet is being taken

NICE indicators. NM33 peripheral arterial disease guidance.

General practice indicator suitable for use in the QOF Published October 2017